Cargando…
Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
OBJECTIVE: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2− metastatic breast cancer (mBC) patients. METHODS: This is a retrospective chart review of 139 postmenopausal HR+/HER2− mBC patients i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560455/ https://www.ncbi.nlm.nih.gov/pubmed/26380551 http://dx.doi.org/10.4137/BCBCR.S30771 |
_version_ | 1782388925446225920 |
---|---|
author | Song, Yan Hao, Yanni Macalalad, Alexander R. Lin, Peggy L. Signorovitch, James E. Wu, Eric Q. |
author_facet | Song, Yan Hao, Yanni Macalalad, Alexander R. Lin, Peggy L. Signorovitch, James E. Wu, Eric Q. |
author_sort | Song, Yan |
collection | PubMed |
description | OBJECTIVE: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2− metastatic breast cancer (mBC) patients. METHODS: This is a retrospective chart review of 139 postmenopausal HR+/HER2− mBC patients initiating first-line ET monotherapy or CT. Overall survival (OS) was described using Kaplan–Meier curves. Exploratory comparative proportional hazards regression was conducted. RESULTS: Patients on first-line CT had significantly more frequent liver metastases than patients on first-line ET monotherapy at baseline. The median OS was 35.5 months [95% confidence interval (CI), 22.7–41.2 months] for patients on first-line ET monotherapy and 22.2 months (95% CI, 13.6–25.9 months) for those on first-line CT (P = 0.021). Adjusting for baseline characteristics, the OS between first-line ET monotherapy and CT was not significantly different. CONCLUSIONS: Patients who were prescribed CT as first-line treatment had evidence of more advanced disease at baseline and shorter OS than those who received ET monotherapy as first-line treatment, suggesting a need for additional safe and effective treatment options for these patients. |
format | Online Article Text |
id | pubmed-4560455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-45604552015-09-17 Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer Song, Yan Hao, Yanni Macalalad, Alexander R. Lin, Peggy L. Signorovitch, James E. Wu, Eric Q. Breast Cancer (Auckl) Original Research OBJECTIVE: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2− metastatic breast cancer (mBC) patients. METHODS: This is a retrospective chart review of 139 postmenopausal HR+/HER2− mBC patients initiating first-line ET monotherapy or CT. Overall survival (OS) was described using Kaplan–Meier curves. Exploratory comparative proportional hazards regression was conducted. RESULTS: Patients on first-line CT had significantly more frequent liver metastases than patients on first-line ET monotherapy at baseline. The median OS was 35.5 months [95% confidence interval (CI), 22.7–41.2 months] for patients on first-line ET monotherapy and 22.2 months (95% CI, 13.6–25.9 months) for those on first-line CT (P = 0.021). Adjusting for baseline characteristics, the OS between first-line ET monotherapy and CT was not significantly different. CONCLUSIONS: Patients who were prescribed CT as first-line treatment had evidence of more advanced disease at baseline and shorter OS than those who received ET monotherapy as first-line treatment, suggesting a need for additional safe and effective treatment options for these patients. Libertas Academica 2015-09-03 /pmc/articles/PMC4560455/ /pubmed/26380551 http://dx.doi.org/10.4137/BCBCR.S30771 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license. |
spellingShingle | Original Research Song, Yan Hao, Yanni Macalalad, Alexander R. Lin, Peggy L. Signorovitch, James E. Wu, Eric Q. Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer |
title | Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer |
title_full | Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer |
title_fullStr | Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer |
title_full_unstemmed | Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer |
title_short | Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer |
title_sort | clinical outcomes with first-line endocrine therapy or chemotherapy in postmenopausal hr+/her2− metastatic breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560455/ https://www.ncbi.nlm.nih.gov/pubmed/26380551 http://dx.doi.org/10.4137/BCBCR.S30771 |
work_keys_str_mv | AT songyan clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer AT haoyanni clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer AT macalaladalexanderr clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer AT linpeggyl clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer AT signorovitchjamese clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer AT wuericq clinicaloutcomeswithfirstlineendocrinetherapyorchemotherapyinpostmenopausalhrher2metastaticbreastcancer |